Provided by Tiger Trade Technology Pte. Ltd.

Dyadic International, Inc.

0.6900
-0.0100-1.43%
Post-market: 0.69000.00000.00%19:34 EDT
Volume:116.18K
Turnover:80.62K
Market Cap:27.64M
PE:-3.24
High:0.7350
Open:0.7080
Low:0.6800
Close:0.7000
52wk High:1.60
52wk Low:0.6546
Shares:40.06M
Float Shares:30.84M
Volume Ratio:0.72
T/O Rate:0.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2129
EPS(LYR):-0.2257
ROE:-2826.92%
ROA:-62.99%
PB:-11.58
PE(LYR):-3.06

Loading ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: ProKidney (PROK), Eton Pharmaceuticals (ETON) and Dyadic International (DYAI)

TIPRANKS
·
Aug 13

Dyadic International Prices Unregistered Warrant Private Placement at $0.005 Per Warrant

Reuters
·
Aug 13

Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement

THOMSON REUTERS
·
Aug 13

Dyadic International Warns of Going-Concern Risk as Dilution, Nasdaq Uncertainty and Noteholder Dependence Threaten Shareholder Value

TIPRANKS
·
Aug 13

Dyadic International Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

Dyadic International Q2 EPS $(0.06) Misses $(0.04) Estimate, Sales $961.138K Miss $993.333K Estimate

Benzinga Earnings
·
Aug 12

Dyadic Net Loss Widens 18.8% to USD 2.12 Million in Q2 FY26; Revenue Slips 0.6% to USD 961,138

Reuters
·
Aug 12

Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas

THOMSON REUTERS
·
Aug 12

Dyadic International Inc Expected to Post a Loss of 4 Cents a Share - Earnings Preview

Reuters
·
Aug 11

Dyadic Signs Development, Commercial License Deal with European Biotech for Precision-Fermented Dairy Proteins

Reuters
·
Aug 04

Dyadic International - Eligible for Development, Commercial Payments and Licensing Revenues Under New Agreement

THOMSON REUTERS
·
Aug 04

Dyadic International - Expands Non-Animal Dairy Pipeline Via New Agreement with European Biotechnology Company

THOMSON REUTERS
·
Aug 04

Dyadic International Updates Financial Calendar, Sets Q2 Results Release and Conference Call

Reuters
·
Aug 04

Dyadic International - Delivers C1-Produced Bundibugyo Ebolavirus Antigens to FBS and Scripps for Preclinical Evaluation

THOMSON REUTERS
·
Jul 28

Dyadic International - Develops C1 Cell Lines and Manufactures Bundibugyo Ebolavirus Antigens Within 15 Days

THOMSON REUTERS
·
Jul 28

Francisco Trust Trustee Thomas Emalfarb Sells 95,392 Dyadic International Common Shares Worth $124,823.82

Reuters
·
Jul 25

Dyadic International regains compliance with Nasdaq

TIPRANKS
·
Jul 24

Dyadic Regains NASDAQ Compliance, Keeps Capital Market Listing

Reuters
·
Jul 24

Dyadic Announces Continued Listing on the NASDAQ Capital Market

THOMSON REUTERS
·
Jul 24

Dyadic International - Regains Compliance with NASDAQ Listing Rules 5550(a)(2) and 5550(b)

THOMSON REUTERS
·
Jul 24